The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major

The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major

Eshghi P¹ ; Amin Asnafi A² ; Shamshiri A¹ ; Alavi S¹ ; Molavi M³ ; Tamaddoni A⁴ ; Keikhaie B² ; Naderi M⁵ ; Hoorfar H⁶ ; Ansari S⁷ ; Azarkeivan A⁸ ; Arasteh M⁹ ; Kourorian Z¹⁰

Show Affiliations

1. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Ahwaz Jondishapour University, Research center for Thalassemia & Hemoglobinopathy, Ahwaz, Iran
3. Department of Pediatric Hematology and Oncology, Bandar Abbas Thalassemia Center, Hormozgan University of Medical Science, Bandar Abbas, Iran
4. Department of Pediatric Hematology and Oncology, Amir Kola Hospital, Babol University of Medical Science, Mazandaran, Iran
5. Department of Pediatric Hematology and Oncology, Ali Asghar Hospital, Zahedan University of Medical Science, Zahedan, Iran
6. Seid-ol-Shohada Hospital, Treatment Center for Special Diseases, Isfahan, Iran
7. Department of Pediatric Hematology and Oncology, Ali Asghar Hospital, Tehran University of Medical Science, Tehran, Iran
8. Zafar center for thalassemia, Iranian Blood Transfusion Organization, Tehran, Iran
9. Samen-ol-Hojaj Center for Special Disease, Kerman, Iran
10. Pharmacovigilance and Medical Information Manager of Ronac Pharmaceutical Company, Tehran, Iran

Source: Iranian Journal of Blood and Cancer Published:2018

Abstract

Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they are not well accepted by the physicians and patients yet. This triple-blind randomized controlled trial was designed to compare the efficacy and safety of a new Iranian generic and the original brand product of Deferoxamine mesylate in Iranian patients. Methods: The present Randomized triple-blind controlled trial research was carried on in nine centers throughout Iran. They were randomly divided into two similar groups and a Cross-over study was designed. 24-hour urine was collected after subcutaneous infusion of either drugs and urinary iron excretion was measured via atomic absorption spectrophotometer device. Acute adverse events during and after drug infusion were recorded. Mack Nara test and p-pair test were applied to compare two cross over interventions. Results: 154 patients from 9 centers were enrolled in this study. There were 95 women and 59 men aged 6-34 years (mean age of 21.1years). Mean urinary iron concentration for Desferal (intervention A) vs. Desfonak (intervention B) groups was 22.5±22.6 vs. 21.5±16.9 mg/m 2 , respectively. Mean urinary iron excretion/ Kg body weight for Desferal (intervention A) vs. Desfonak (intervention B) groups was 0.48±0.48 vs. 0.47±0.40 mg/m 2 , respectively. Conclusion: According to the results of this study, there was similarity between efficacy and safety of the original and generic brands of deferoxamine (desferal vs. desfonac). © 2018, Iranian Pediatric Hematology and Oncology Society. All rights reserved.

Related Docs

View other Related Docs

1. Efficacy and Safety of Iranian Made Deferasirox (Osveral®)In Iranian Major Thalassemic Patients With Transfusional Iron Overload: A One Year Prospective Multicentric Open-Label Non-Comparative Study, DARU, Journal of Pharmaceutical Sciences (2011)

2. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)

3. The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in Β-Thalassemia Patients, Iranian Journal of Pediatric Hematology and Oncology (2019)

4. An Evaluation of Sensory Neural Hearing Loss in Thalassaemic Patients Treated With Desferrioxamine and Its Risk Factors, Journal of Research in Medical Sciences (2005)

5. Combined Therapy of Silymarin and Desferrioxamine in Patients With Β-Thalassemia Major: A Randomized Double-Blind Clinical Trial, Fundamental and Clinical Pharmacology (2009)

6. Protective Role of Silymarin and Deferoxamine Against Iron Dextran-Induced Renal Iron Deposition in Male Rats, International Journal of Preventive Medicine (2013)

7. Effectiveness of Twice Weekly Iron Supplementation Compared With Daily Regimen in Reducing Anemia and Iron Deficiency During Pregnancy: A Randomized Trial in Iran, Journal of Research in Medical Sciences (2008)

8. Co-Administration of Silymarin and Deferoxamine Against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model, International Journal of Preventive Medicine (2014)

Experts (# of related papers)

View all Related Experts

Mohammad Reza Maracy (3)

Mehdi Nematbakhsh (2)

Style	Citing Format
MLA	Eshghi P, et al.. "The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major." Iranian Journal of Blood and Cancer, vol. 9, no. 4, 2018, pp. 108-111.
APA	Eshghi P, Amin Asnafi A, Shamshiri A, Alavi S, Molavi M, Tamaddoni A, Keikhaie B, Naderi M, Hoorfar H, Ansari S, Azarkeivan A, Arasteh M, Kourorian Z (2018). The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major. Iranian Journal of Blood and Cancer, 9(4), 108-111.
Chicago	Eshghi P, Amin Asnafi A, Shamshiri A, Alavi S, Molavi M, Tamaddoni A, Keikhaie B, et al.. "The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major." Iranian Journal of Blood and Cancer 9, no. 4 (2018): 108-111.
Harvard	Eshghi P et al. (2018) 'The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major', Iranian Journal of Blood and Cancer, 9(4), pp. 108-111.
Vancouver	Eshghi P, Amin Asnafi A, Shamshiri A, Alavi S, Molavi M, Tamaddoni A, et al.. The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major. Iranian Journal of Blood and Cancer. 2018;9(4):108-111.
BibTex	@article{ author = {Eshghi P and Amin Asnafi A and Shamshiri A and Alavi S and Molavi M and Tamaddoni A and Keikhaie B and Naderi M and Hoorfar H and Ansari S and Azarkeivan A and Arasteh M and Kourorian Z}, title = {The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major}, journal = {Iranian Journal of Blood and Cancer}, volume = {9}, number = {4}, pages = {108-111}, year = {2018} }
RIS	TY - JOUR AU - Eshghi P AU - Amin Asnafi A AU - Shamshiri A AU - Alavi S AU - Molavi M AU - Tamaddoni A AU - Keikhaie B AU - Naderi M AU - Hoorfar H AU - Ansari S AU - Azarkeivan A AU - Arasteh M AU - Kourorian Z TI - The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major JO - Iranian Journal of Blood and Cancer VL - 9 IS - 4 SP - 108 EP - 111 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract